Out of the blue we’ve heard from some smart people interested in this obscure molecular diagnostics company. Yet it seems few really know what’s going on in this space. All the focus is on the FDA clearance of Luminex’s new platform, Aries, which was designed to appeal to hospitals that might otherwise send out complex molecular tests to academic centers or big labs. In this podcast, Bill Baker, CFA, reveals how despite murky corporate-level profit patterns and the excitement about Aries, a quietly building strength in high-margin royalties, assays, and consumables separates Luminex from the rest of the pack. He shares his insight from years of following a number of molecular diagnostic firms, and debunks misconceptions of where profitability really originates at competitors that would be affected by the launch of Aries. Next week Bill travels to attend the Association for Molecular Pathology annual meeting in Austin, TX.